Finance & Accounting

Biopharmaceutical finance and market access teams face four critical business challenges: inefficiency and rework, risky manual processes, financial statement errors, and audit and compliance issues. These challenges intensify as teams attempt to accurately accrue the vast number of rebates, discounts, chargebacks, administrative fees, copay programs, and other sales-related adjustments across an increasingly complex commercial landscape.

Common challenges include:

• Inaccuracy of pricing, discount, copay, inventory, and returns data
• Forecasting models lacking a clear, documented, and audit-ready methodology
• Fragile, error-prone spreadsheet models that lack effective version control
• Fragmented data and siloed departments operating from independent GTN spreadsheets
• Difficulty hiring and retaining GTN talent

IntegriChain's GTN Accruals solution automates the entire accrual lifecycle- from data ingestion and cleansing through calculation execution, balance sheet roll-forward, and financial close, eliminating manual processes and delivering the bottoms-up transparency that finance teams and auditors demand. The platform comes pre-configured with accrual methodologies for all standard GTN line items, including prior period true-ups, inventory pipeline adjustments, and a dedicated URA, Best Price, and TRICARE calculator. Seamless integration with revenue management systems and ERP platforms, combined with pre-built operational reports, a full-suite analytics dashboard, and scalability and auditability built in from day one, makes it a comprehensive solution for modern GTN management.

ICyte's industry-leading GTN forecasting capabilities empower finance and market access teams to build and maintain financial models that accurately forecast net revenue by payer and channel, with full visibility into historical inputs, assumptions, and transactions. The platform offers out-of-the-box forecasting methodologies for each GTN line item, a contract and mandated rate repository, and calculators for URA, Best Price, ASP, and TRICARE. Robust what-if scenario modeling captures the net revenue impact of WAC pricing changes, contract term adjustments, legislation, AMP and URA fluctuations, 340B/PHS pricing, and Medicaid program participation, all supported by variance analysis, side-by-side scenario comparison, and pre-configured reports and dashboards.